Drug major Aurobindo Pharma Ltd said on Monday it expects regulatory action leading to the worldwide recall of its hypertension product valsartan will not impact growth.
The company said it was confident that the contamination in valsartan will not spread to other products.
"From a cleaning
"From a cleaning